title: [Thalidomide teratogenicity and its direct target identification].
abstract: Half a century ago, thalidomide was developed as a sedative drug and was wildly used over 40 countries. However the drug has serious birth defects such as amelia and phocomelia. Now thalidomide is regarded as a clinically effective drug and used for the treatment of multiple myeloma under strict controls. The direct target of thalidomide had been a long-standing question. We identified cereblon as a primary direct target protein for thalidomide teratogenicity using new affinity bead technology in 2010. In this review, we introduce an overview of thalidomide teratogenicity, a story about how we identified cereblon, and recent advances in cereblon studies.
authors.forename: Takumi
authors.initials: T
authors.lastname: Ito
authors.forename: Hideki
authors.initials: H
authors.lastname: Ando
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Handa
mesh_terms: D048868:Adaptor Proteins, Signal Transducing; D000818:Animals; D006801:Humans; D058990:Molecular Targeted Therapy; D009101:Multiple Myeloma / Q000188:drug therapy*; D010447:Peptide Hydrolases / Q000378:metabolism; D064793:Teratogenesis; D013792:Thalidomide / Q000009:adverse effects / Q000737:chemistry / Q000627:therapeutic use*; D044767:Ubiquitin-Protein Ligases
chemical_list: D048868:Adaptor Proteins, Signal Transducing; C502543:CRBN protein, human; D013792:Thalidomide; D044767:Ubiquitin-Protein Ligases; D010447:Peptide Hydrolases